You are not currently logged in.
Access JSTOR through your library or other institution:
High Frequency of Clinically Significant Mutations after First-Line Generic Highly Active Antiretroviral Therapy Failure: Implications for Second-Line Options in Resource-Limited Settings
N. Kumarasamy, Vidya Madhavan, Kartik K. Venkatesh, S. Saravanan, Rami Kantor, P. Balakrishnan, Bella Devaleenal, S. Poongulali, Tokugha Yepthomi, Suniti Solomon, Kenneth H. Mayer, Constance Benson and Robert Schooley
Clinical Infectious Diseases
Vol. 49, No. 2 (Jul. 15, 2009), pp. 306-309
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/40308672
Page Count: 4
You can always find the topics here!Topics: Genetic mutation, Medical treatment failures, Highly active antiretroviral therapy, HIV, Drug resistance, Immunology, AIDS, Viral load, Educational research, Virology
Were these topics helpful?See somethings inaccurate? Let us know!
Select the topics that are inaccurate.
Preview not available
Continuation of failed highly active antiretroviral therapy regimens can lead to the accumulation of mutations that may limit options for second-line treatment. We studied the pattern of drug resistance mutations among 138 Indian patients who experienced failure of nonnudeotide reverse-transcriptase-containing first-line highly active antiretroviral therapy. This study demonstrates a high frequency of drug resistance mutations in human immunodeficiency virus-infected Indians who experience immunologic treatment failure and suggests the need for viral load monitoring.
Clinical Infectious Diseases © 2009 Oxford University Press